Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric roxadustat study for anemia in chronic kidney disease
2022-501980-42-00Phase 3Authorised
- Sponsor
- Astellas Pharma
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, open-label trial of roxadustat in anemia of renal disease (2 arms), sponsored by Astellas Pharma. Primary endpoint: Change in hemoglobin from baseline to weeks 20 to 24 average. Planned start Dec 2023; status: authorised.
02
Drugs
roxadustat
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on 2022-501980-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501980-42-00.